Brentuximab vedotin plus chemotherapy for CD30+ T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well a combination drug treatment (brentuximab vedotin plus chemotherapy) works for patients with rare T-cell lymphomas in real-world clinical practice in Spain. It focuses on patients receiving this as their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a CD30-positive peripheral T-cell lymphoma (such as anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, or related subtypes)
- You are 18 years of age or older
- You received brentuximab vedotin plus CHP chemotherapy as your very first lymphoma treatment
- Your treatment occurred between January 2019 and September 2024
- You have not received any other treatment for your lymphoma before this combination
- You did not receive this drug combination as part of a separate clinical trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, chidamide and brentuximab vedotin, for people with a type of T-cell lymphoma that has the CD30 protein. It is for patients who are older or not healthy enough for standard chemotherapy, and whose cancer has come back or not responded to previous treatment.
This trial tests a new combination of drugs for people with a type of lymphoma called EBV-positive DLBCL that has not been treated before. The goal is to see if adding brentuximab vedotin to the standard R-CHP chemotherapy can improve outcomes.
This trial is a survey study that looks at how brentuximab vedotin is used in children with Hodgkin lymphoma. It focuses on people whose tumor is CD30-positive and who have not had prior treatment, to see how the drug fits with a standard chemotherapy plan (AVD).
This trial tests whether adding the drugs brentuximab and etoposide to standard chemotherapy improves treatment for people newly diagnosed with T-cell lymphoma. It aims to find a more effective first treatment option.
This early-phase study tests a lymphoma treatment in adults whose diffuse large B-cell lymphoma (DLBCL) is “CD30-positive” and who didn’t respond well to first-line chemotherapy (like R-CHOP) or had an early relapse. It aims to see if the treatment can shrink the lymphoma and is safe enough to move forward.
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
Hear when a new CD30-Positive Peripheral T-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.